Sign In
Buy SMMT
$15.07
+0.210 (+1.41%)
At Close: Jun 03, 2026
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
03:54am, Tuesday, 24'th Feb 2026
Summit Therapeutics Inc. (SMMT) Q4 2025 Earnings Call Transcript
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025
04:05pm, Monday, 23'rd Feb 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today reports its financial results and provides an update on clinical and operational prog
Illinois Municipal Retirement Fund Increases Stake in Summit Therapeutics PLC $SMMT
04:03am, Wednesday, 18'th Feb 2026
Illinois Municipal Retirement Fund increased its stake in Summit Therapeutics PLC (NASDAQ: SMMT) by 121.1% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026
05:05pm, Tuesday, 17'th Feb 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) will host an earnings call to announce its fourth quarter and full year 2025 fi
2 Stocks That Could Soar This Year
06:53pm, Saturday, 31'st Jan 2026
Exelixis and Summit Therapeutics could have significant catalysts this year. Both have drug candidates that could drive strong financial results for a while.
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:30pm, Friday, 30'th Jan 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
FDA Accepts SMMT's Application Seeking Approval for NSCLC Drug
11:25am, Friday, 30'th Jan 2026
Summit Therapeutics' ivonescimab BLA wins FDA acceptance for EGFR-mutated NSCLC, with a PDUFA action date of Nov. 14, 2026.
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced that the U.S. Food & Drug Administration (FDA) has accepted for filing Summ
Regencell led last week's large-cap losers as Figma, Atlassian and Trip.com slid on downgrades, probes and broader tech weakness.
Summit Therapeutics PLC (NASDAQ:SMMT) Receives Consensus Rating of “Hold” from Brokerages
03:50am, Thursday, 15'th Jan 2026
Summit Therapeutics PLC (NASDAQ: SMMT - Get Free Report) has been assigned a consensus recommendation of "Hold" from the seventeen ratings firms that are covering the company, Marketbeat.com reports.
Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
03:56pm, Monday, 12'th Jan 2026
Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
2 Biotech Stocks That Could Soar This Year
11:45am, Monday, 12'th Jan 2026
Both biotechs are a bit risky, but could benefit from clinical progress this year -- and the upside would be huge. CRISPR has three promising candidates in early development as well as its only approv
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced it has entered into a clinical trial collaboration with GSK plc (“GSK”, LSE/NYSE: GSK) to evaluate ivonesc
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that it has submitted a Biologics License Application (BLA) to
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
08:16pm, Friday, 09'th Jan 2026
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) ("Summit," "we," or the "Company") today announced the grant of inducement awards of options to purchase a collective total of
